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In Brief
Menon, Firth, and colleagues show that
TALEN-mediated correction of a novel
splice site mutation in the IL-2Rg gene
rescues defective development of mature
NK cells from iPSCs derived from a SCID-
X1 subject. They demonstrate correction
of the aberrant splicing of the IL-2Rg in
T cell precursors.
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X-linked SevereCombined Immunodeficiency (SCID-
X1) is a genetic disease that leaves newborns at high
risk of serious infection and a predicted life span of
less than 1 year in the absence of a matched bone
marrow donor. The disease pathogenesis is due to
mutations in the gene encoding the Interleukin-2
receptor gamma chain (IL-2Rg), leading to a lack of
functional lymphocytes. With the leukemogenic con-
cerns of viral gene therapy there is a need to explore
alternative therapeutic options. We have utilized in-
duced pluripotent stem cell (iPSC) technology and
genome editing mediated by TALENs to generate
isogenic subject-specificmutant andgene-corrected
iPSC lines. While the subject-derived mutant iPSCs
have the capacity to generate hematopoietic precur-
sors and myeloid cells, only wild-type and gene-cor-
rected iPSCs can additionally generate mature NK
cells and T cell precursors expressing the correctly
spliced IL-2Rg. This study highlights the potential
for the development of autologous cell therapy for
SCID-X1 subjects.
Primary immunodeficiencies (PIDs) constitute a large and het-
erogeneous group of rare heritable disorders, including X-linked
Severe Combined Immunodeficiency (SCID-X1), Adenosine
deaminase deficiency-SCID (ADA-SCID), and Wiskott-Aldrich
syndrome (WAS), that result in an underdeveloped and/or func-
tionally compromised immune system. Allogeneic hematopoiet-
ic stem cell transplant (HSCT) from a matched donor confers
significant therapeutic benefit with over 90% success rates;
however, the scarcity of HLA-matched donors makes this
approach less universally viable (Mukherjee and Thrasher,
2013). Autologous transplantation of hematopoietic stem cells
(HSCs) genetically corrected by targeted genome editing hasbeen shown to be efficacious in proof-of-concept studies (Geno-
vese et al., 2014) and even clinically effective upon lentiviral gene
therapy for subjects with metachromatic leukodystrophy (Aiuti
et al., 2013) and WAS (Biffi et al., 2013). However, these autolo-
gous HSCT-based approaches are limited by imperfect method-
ologies for the culture and expansion of HSCs ex vivo.
SCID-X1 is an inherited disorder affecting the immune system.
It is caused by mutations in the common receptor gamma chain,
a subunit of several cytokine receptors, including interleukin-2,
-4, -7, -9, -15 and -21, that commonly leads to a lack of
T cells, functional B cells, and Natural Killer (NK) cells, leaving
these subjects severely immune compromised. SCID-X1 affects
males with an estimated incidence of 1:50,000 newborns and
these individuals are at high risk of infection due to defective
generation of early lymphoid progenitors. Without treatment,
life expectancy is less than 1 year with a poor quality of life. A
proven cure is transplantation of HLA-matched bone marrow;
however, such subject-matched donors are relatively limited in
supply.
Gene therapy trials on SCID-X1 subjects were initiated in 1999
and promising initial results emerged showing T, B, and NK cell
function comparable to that in age-matched controls (Cavaz-
zana-Calvo et al., 2000). Unfortunately, after the development
of T cell acute lymphoblastic leukemia (T-ALL) as a consequence
of vector-mediated genotoxicity, the trials were prematurely
halted in 2003 and a new therapeutic approach is still sought
(Hacein-Bey-Abina et al., 2003, 2008).
Transcription activator-like effectors (TALEs) from the plant
pathogen Xanthomonas are sequence-specific DNA-binding
proteins (Bogdanove et al., 2010; Kay and Bonas, 2009; Kay
et al., 2007; Ro¨mer et al., 2007) that can be engineered to bind
any desired target sequence (Boch et al., 2009; Moscou and
Bogdanove, 2009). A pair of TALE nucleases (TALENs) can be
used to generate a double-strand break (DSB) at a specific
genomic locus and consequently to mediate homologous
recombination (HR) (Bedell et al., 2012). TALENs have been suc-
cessfully employed to mediate site-specific genome modifica-
tion by HR in human pluripotent stem cells (Hockemeyer et al.,Cell Stem Cell 16, 367–372, April 2, 2015 ª2015 Elsevier Inc. 367
Figure 1. TALEN-Mediated Gene Correction and Lymphoid Differentiation of SCID-X1 iPSCs
(A) Schematic representation of the IL-2Rg gene, the endogenous target locus of our subject-specific mutation, and the corrective donor vector used. The
sequence of the subject-specific IL-2Rg splice-site target mutation and the corrective donor vector sequence are also shown below. The point mutation causing
(legend continued on next page)
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2011), which offers the potential of an alternative gene/stem cell
therapeutic approach.
NK cells are a key component of innate immunity and central
to the host immune defense against pathogens and tumors
(Biron et al., 1999; Vivier et al., 2011). NK cells have been suc-
cessfully differentiated from CD34+ cord blood cells (Kao et al.,
2007; Meek et al., 2010). Differentiation from pluripotent stem
cells has proved somewhat harder to accomplish. Initial studies
identified putative NK cells from the differentiation of hESCs and
iPSCs; however, these cells were characterized based solely on
their expression of CD56 and the characterization lacked anal-
ysis of the functional receptors expressed on mature NK cells
(Tabatabaei-Zavareh et al., 2007). As NK cells mature they start
to express both activating and inhibitory receptors that regulate
NK cell activity. Killer cell Ig-like receptors (KIRs) and CD94/
NKG2 heterodimers are two major receptor types that interact
with MHC on target cells. For iPSCs, however, the yield is
considerably lower than for ESCs (Ni et al., 2011).
In the current study we were able to generate provirus-free
iPSC lines from a SCID-X1 subject, correct the genetic defect
utilizing TALENs, and differentiate these cells in vitro to NK cells
expressing mature NK cell markers. Notably, while all tested
lines were capable of generating myeloid and endothelial cells,
only the wild-type and gene-corrected lines could differentiate
into NK cells and demonstrated the presence of a correctly
spliced IL-2Rg. This is the first evidence of genomic correction
of SCID-X1 subject iPSCs resulting in the regeneration of mature
lymphoid cells in vitro and holds great promise for the develop-
ment of novel therapeutic approaches for this incurable and ter-
minal disease.
Eight iPSC lines were derived from bone marrow multipotent
stem cells (BM-MSCs) from an infant with SCID-X1 using
a Cre-excisable lentiviral vector containing six reprogramming
factors (Firth et al., 2014). Control iPSCs were also gener-
ated from cord-blood-derived endothelial cells and dermal
fibroblasts.
The donor subject harbored a novel splice-site mutation,
c.468+3A > C, of the IL-2Rg. This specific mutation results in a
lack of functional NK cells and T cells (Ginn et al., 2004). The
mutation is an A to C substitution in the third base pair of intron
3 of the IL-2Rg gene, leading to aberrant splicing of the IL-2Rg
transcript. TALEN pairs were designed to target genomic se-
quences proximal to the describedmutation (Figure 1A) and their
functional activity at the desired target locus was validated
(Figure S1A). The target SCID-X1 mutation was corrected by
co-nucleofection of these TALENs in combination with a donor
plasmid containing the corrective DNA sequence (Figure 1A).the alteration of this exon/intron consensus splice site is indicated in red. Exon 3 s
in bold. TALEN binding sites are indicated by black arrows.
(B) Identification and isolation of corrected iPSCs through single-cell clonal amplifi
specific to the correction event. Corrected clones and subclones are identified b
(C) Chromatogram of the corrected iPSC clone indicated in Figure 1B, as verified
introduced to abolish TALEN activity on the corrective or corrected DNA sequen
(D) Comparative analysis of FACS data from wild-type, SCID-X1 mutant, and SC
differentiation. Isotype controls are included in the left panel.
(E) RT-PCR analysis of RNA extracted from T cell precursors in the floating fraction
corrected iPSC clones.
(F) FACS analysis of the floating fraction of cells co-cultured on OP9-DL feeders fr
iPSC lines. CD45+ and CD45+/CD4+/CD8a+ populations are indicated.Corrected clones identified upon screening are shown in Fig-
ure 1B. Correction of the IL-2Rg gene in each clone was verified
by sequencing an integration-specific PCR product of the target
genomic DNA, where correction of the target mutation at the
endogenous chromosomal locus was detected along with the
presence of silent mutations introduced in the corrective seq-
uence (Figure 1C). Integration of the corrective IL-2Rg sequence
at its desired endogenous chromosomal locus was achieved at
an overall efficiency of 2.6% without selection. The presence
of the desired genetic correction and introduced silent mutations
was confirmed by whole-exome sequencing of the corrected
and parental iPSC lines, which also verified the lack of significant
off-target effects in any coding sequence due to gene correction
with TALENs (Figure S1).
The interleukin signaling affected by mutations in the common
gamma chain should only have a significant impact on lymphoid
differentiation and not on other hematopoietic lineages. As ex-
pected, each iPSC line was capable of proficiently generating
CD34+ hematopoietic progenitor cells and cells with cell surface
markers of a hematopoietic stem cell—CD90+ CD34+, CD43+,
and CD38—which acquired CD45 expression upon commit-
ment to the myeloid lineage (Figures 1D and S2A). The mutant
and corrected cell lines tested showed a similar capacity for
generating mature myeloid colony forming units (CFUs) in a
methylcellulose-based maturation assay (Figure S2B). After
14 days of myeloid maturation, each line was equally capable
of generating CD45+ CD14+ monocytes and CD45+ Glycophorin
A+ erythroid progenitors (Figure S2C).
CD34+ progenitor cells derived from embryoid bodies (EBs)
were sorted at day 8 of differentiation and plated on OP9 cells
overexpressing DL-1. After 14 days of differentiation on OP9-
DL-1 in the presence of IL-7, we were able to generate CD45+
cells in the floating fraction that also co-expressed CD4 and
CD8a. The mutant SCID-X1 line only generated CD45+ cells;
no significant population of CD4+/CD8a+ cells was observed
(Figure 1F). We were able to see the rescue of the aberrant
splicing of the IL-2Rg transcript in CD45+ T cell precursors
derived from the gene-corrected iPSC lines as compared to
the subject iPSC-derived mutant CD45+ cells (Figure 1E,
compare lane 5 with 4, 6, and 7).
To determine whether lymphoid potential was restored in the
corrected iPSC line, we first produced HSCs from day 15 EB cul-
tures from each of the indicated GFP-transduced iPSC lines, pu-
rified them based on CD34 expression, and transferred these to
AFT024 layer cultures (Ni et al., 2011). Hematopoietic precursors
isolated fromSCID-X1mutant iPSCs did not differ markedly from
those of the various controls, generating similar percentages ofequence immediately preceding the splice site is denoted by green, with bases
cation and screening of the PCR products with an XmaI restriction digest that is
y (#).
by sequencing. The red boxes indicate each of the silent mutations that were
ces. Black box indicates the corrected disease-causing base.
ID-X1 corrected iPSCs. Data show CD34 and CD43 expression at day 13 of
generated fromwild-type, subject-derived SCID-X1mutant iPSCs, or SCID-X1
om two independent wild-type, SCID-X1 mutant, and SCID-X1 gene-corrected
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CD34+ in EB culture by day 15 (Figure 2A). HSCs derived from all
lines generated cells that could progress to early immature NK
cells as indicated by expression of CD122 and extremely low
level expression of CD117 (c-kit), CD161, and CD56 (Figure 2B).
Thus, in vitro, this subject’s defect in common g-chain signaling
does not prevent entry and early progression within the NK
lineage.
By day 20, however, differences become evident when CD94
and CD56 emerge in control and corrected SCID-X1 cultures but
are absent in SCID-X1 cells (data not shown). The difference be-
comes much more pronounced as the cells progress; by day 33
of culture there is a clear defect in differentiation of the SCID-X1
cells. This suggests that these cells cannot pass into the early
immature NK developmental stage as defined by expression of
these two markers (Figure 2C). Similarly, while SCID-X1-derived
cells in AFT culture are clearly hematopoietic, because they
strongly express CD45, they are negative for CD335, a marker
uniquely expressed on NK cells (Figure 2C). To rule out the pos-
sibility that the SCID-X1 cells were slower in developing than the
wild-type or gene-corrected cells, we continued a long-term dif-
ferentiation to day 41, at which point very few CD45+ SCID-X1
cells remain, and no evidence for their further development
was observed. In contrast, the gene-corrected and control lines
progressed to mature NK status, expressing both inhibitory and
activating receptors (KIR/CD158b andCD16, respectively) found
onmature NK cells (Figure 2D). These cells continued to express
CD335, which was never observed in themutant cells. This dem-
onstrates that correction of the IL-2Rg mutation in SCID-X1
iPSCs results in restored developmental progression along the
NK lineage to cells expressing multiple mature NK cell markers.
In this report, we have demonstrated that the precise correc-
tion of a novel splice-site mutation of the IL-2Rg gene at its
endogenous genomic locus in subject-derived iPSCs results in
the correction of the splicing defect of the IL-2Rg transcript
and thus rescues the ability of iPSCs to differentiate into NK cells.
It is the first report, to our knowledge, to describe the derivation
of iPSCs from a SCID-X1 subject and the functional gene correc-
tion of a point mutation using genome editing technology using a
selection-free approach. Upon gene correction, we generated
mature NK cells and T cell precursors that were otherwise
abnormal or missing in the subject.
Improved viral approaches for gene therapy have been devel-
oped since the original SCID-X1 clinical trials (Hacein-Bey-Abina
et al., 2002). Lentiviral gene therapy using autologous HSCs has
proven initially efficacious in the treatment of WAS (Aiuti et al.,
2013; Verma, 2013) and metachromatic leukodystrophy (Biffi
et al., 2013) subjects. An ongoing clinical trial using a self-inacti-
vating g-retrovirus vector to transduce autologous CD34+ HSCs
with the IL-2Rg gene for transplantation in nine SCID-X1 sub-
jects has also shown early clinical benefits (Hacein-Bey-Abina
et al., 2014); these studies require long-term follow-up to conclu-
sively determine the safety of this approach. Leukemogenic
outcomes were observed in the original trial as late as 68monthsFigure 2. Generation of Mature NK Cells
FACS analysis of dissociated cells from H1-Embryonic Stem Cells (ESC), wild-ty
antigens indicated on the left at the following time points: (A) embryoid bodies (E
culture; and (C) immature NK cells at day 33 of AFT culture. The red arrow highlig
day 41 of AFT culture. Cell percentages are indicated at the corner of each gateafter gene therapy. All viral gene therapy vectors involve integra-
tion into the host genome and consequently bear the risk of
insertional mutagenesis on a subject-to-subject basis.
Direct genome editing of subject-derived CD34+ HSCs using
zinc finger nucleases (ZFNs) was shown in a recent proof-of-
concept study (Genovese et al., 2014). While this is an attractive
alternative to viral gene therapy, these approaches are depen-
dent on the hitherto elusive capability to efficiently culture
and expand long-term repopulating HSCs ex vivo. In addition,
HSCT-based approaches involve myeloablative pre-transplant
conditioning, which poses a particularly high level of risk for
these SCID-X1 subjects, given their very young age and highly
immune-compromised state. An iPSC-based approach pro-
vides an unlimited source of subject-derived, corrected cells
from which immune cells can be derived continuously for trans-
fusion, and this approach could serve as a complementary
approach to treat subjects.
Adoptive transfer of NK cells is already being used to treat a
number of malignancies (Geller et al., 2011; Ruggeri et al.,
2002), thus creating an unlimited source of subject-specific NK
cells, which could provide significant clinical benefit in the treat-
ment and management of SCID-X1 and similar diseases. Further
improvements and scaling up of our current protocols will be
necessary to obtain sufficient cells for use in a clinical context.
In summary, we have described here the precise genetic correc-
tion of a SCID-X1 subject-derived iPSC line, and importantly, we
provide evidence for recovery of lymphoid differentiation from
these isogenic gene-corrected iPSCs, creating an ideal platform
for improved modeling and therapy of SCID-X1 and similar PIDs.
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